NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary

NewAmsterdam Pharma (Nasdaq:NAMS) announced inducement stock option grants for a newly hired non-executive employee under the 2024 Inducement Plan in accordance with Nasdaq Listing Rule 5635(c)(4).

The Compensation Committee approved options covering 20,000 ordinary shares with an exercise price of $35.20 per share, equal to the closing Nasdaq price on January 2, 2026. The options vest over four years: 25% on the one-year anniversary of the vesting commencement date, then the remaining shares in 36 equal monthly installments, subject to continued service, and are governed by the 2024 Inducement Plan and an option award agreement.

News Market Reaction – NAMSW

+3.68%

1 alert

+3.68% News Effect

On the day this news was published, NAMSW gained 3.68%, reflecting a moderate positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

NAARDEN, the Netherlands and MIAMI, Jan. 05, 2026 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or well-tolerated, today announced that the Compensation Committee of NewAmsterdam’s Board of Directors approved the grant of inducement share options covering an aggregate of 20,000 of NewAmsterdam’s ordinary shares to one non-executive new hire. The share options were granted as an inducement material to the employee’s acceptance of employment with NewAmsterdam pursuant to the NewAmsterdam Pharma Company N.V. 2024 Inducement Plan (the “2024 Inducement Plan”) and in accordance with Nasdaq Listing Rule 5635(c)(4).

The share options have an exercise price per share equal to $35.20, which represents the closing market price on the Nasdaq Stock Market of the Company’s ordinary shares on January 2, 2026, the grant date. The shares subject to the options will vest over four years, with 25% of the shares vesting on the one-year anniversary of the applicable vesting commencement date and the balance of the shares vesting in a series of 36 equal monthly installments thereafter, subject to the employee’s continued service with NewAmsterdam on such vesting dates. The options are subject to the terms and conditions of the 2024 Inducement Plan and the terms and conditions of an option award agreement covering the grant.

About NewAmsterdam
NewAmsterdam Pharma (Nasdaq: NAMS) is a late-stage biopharmaceutical company whose mission is to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. We seek to fill a significant unmet need for a safe, well-tolerated and convenient LDL-lowering therapy. In multiple phase 3 studies, NewAmsterdam is investigating obicetrapib, an oral, low-dose and once-daily CETP inhibitor, alone or as a fixed-dose combination with ezetimibe, as LDL-C lowering therapies to be used as an adjunct to statin therapy for patients at risk of CVD with elevated LDL-C, for whom existing therapies are not sufficiently effective or well tolerated.

Company Contact
Matthew Philippe
P: 1-917-882-7512
matthew.philippe@newamsterdampharma.com

FAQ

What did NewAmsterdam (NAMS) announce on January 5, 2026 regarding option grants?

NewAmsterdam announced inducement options covering 20,000 shares granted to one non-executive new hire under the 2024 Inducement Plan.

What is the exercise price and grant date for the NAMS inducement options?

The exercise price is $35.20 per share, equal to the closing Nasdaq price on the grant date of January 2, 2026.

How do the NewAmsterdam (NAMS) options vest and what is the vesting schedule?

Options vest over four years: 25% at the one-year anniversary and the remainder in 36 equal monthly installments, subject to continued service.

Under which Nasdaq rule were the NewAmsterdam (NAMS) inducement awards approved?

The awards were approved pursuant to Nasdaq Listing Rule 5635(c)(4), which covers inducement grants for newly hired employees.

Who approved the inducement option grant at NewAmsterdam (NAMS)?

The Compensation Committee of NewAmsterdam’s Board of Directors approved the grant.

Are the NAMS inducement options subject to additional terms or agreements?

Yes, the options are subject to the terms of the 2024 Inducement Plan and an individual option award agreement.